The activation of cGAS-STING pathway boosts anti-tumor immunity by inducing type I interferon production, which in turn promotes dendritic cell (DC) priming and T cell priming in the tumor microenvironment (TME) [6–8]. Here, STING1 is linked to neoplasm.